Navigation Links
OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Date:11/2/2009

BOTHELL, WA and VANCOUVER Nov. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company will announce third quarter financial results after the market closes on Thursday, November 5, 2009. OncoGenex will host a conference call and live webcast at 4:30 p.m. ET that afternoon to provide a business update and discuss the third quarter results.

A live webcast will be available through the Events and Presentations Web page found in the Investor Relations section of the OncoGenex Web site at www.ir.oncogenex.com. Alternatively, you may access the live conference call by dialing 888-466-4520 (U.S. & Canada) or 719-457-2729 (International). A webcast replay will be available approximately two hours after the call and will be archived at the same Web location for 90 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in phase 1 clinical development; SN2310 has completed a phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)... , July 30, 2015 Ascendis ... company that applies its innovative TransCon technology to ... top-line results from a six-month Phase 2 study ... TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children ... "We are extremely pleased with the top-line results ...
(Date:7/29/2015)... 30, 2015 Sanofi, a ... the second quarter of 2015. CEO Olivier ... its performance in different businesses. Watch ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in the ... - Performance drivers - Diabetes ...
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
Breaking Biology Technology:Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... senior vice,president and co-director of the Vaccine and ... today was named as one of 65 new,members ... Election to the IOM is considered one of ... medicine and recognizes individuals who have,demonstrated outstanding professional ...
... October 13 Mentice, a leading,supplier of solutions ... Larsson as Vice President of Global Marketing., ... up and coordinate,Mentice,s marketing activities globally from a ... over 15 years of experience of global,sales, marketing ...
... Mass., Oct. 13 Proteon Therapeutics is,presenting ... of the potential of PRT-201 to enhance ... arterial disease (PAD). The,presentation, entitled, "Local Catheter-Directed ... and Restenosis," is being made at the ...
Cached Biology Technology:Mentice Appoints Bjorn Larsson as Vice President of Global Marketing 2Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008 2
(Date:7/2/2015)... 2015 Research and Markets( ... "Next Generation Biometrics Market by Application, Technology, Function & ... their offering. The next generation biometrics market ... a CAGR of 17.9% between 2015 and 2020 ... the market. Safran SA ( France ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... Barry T. Katzen, M.D., FSIR, an interventional radiologist ... & Vascular Institute in Miami, Fla., was awarded ... II MD Award for Physician Excellence. This prestigious ... or patient care in vascular disease. "For ...
... unlikely the United States will meet some specific biofuel ... unless innovative technologies are developed or policies change, says ... Council, which adds that the standard may be an ... Achieving this standard would likely increase federal budget outlays ...
... Cell-penetrating peptides, such as the HIV TAT peptide, ... mechanisms, from direct entry to endocytosis, a process by ... these cell-penetrating peptides, or CPPs, can facilitate the cellular ... to nano-sized particles and large fragments of DNA. Because ...
Cached Biology News:Society of Interventional Radiology member receives award for career contributions 2Society of Interventional Radiology member receives award for career contributions 3Certain biofuel mandates unlikely to be met by 2022; unless new technologies, policies developed 2Certain biofuel mandates unlikely to be met by 2022; unless new technologies, policies developed 3Certain biofuel mandates unlikely to be met by 2022; unless new technologies, policies developed 4UCLA study shows cell-penetrating peptides for drug delivery act like a Swiss Army Knife 2UCLA study shows cell-penetrating peptides for drug delivery act like a Swiss Army Knife 3
Immunogen: Recombinant full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... Immunogen: Synthetic peptide derived from ... and bovine Math-2. Specificity: Specific ... Human Rat (positive controls: human U251 ... lysates and rat brain homogenates)Storage: Store ...
...
Biology Products: